

Matthew T Roe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4334602/publications.pdf>

Version: 2024-02-01

237
papers

15,869
citations

18482

62
h-index

18647

119
g-index

238
all docs

238
docs citations

238
times ranked

13307
citing authors

#	ARTICLE	IF	CITATIONS
1	Baseline Risk of Major Bleeding in Non-ST-Segment Elevation Myocardial Infarction. <i>Circulation</i> , 2009, 119, 1873-1882.	1.6	876
2	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. <i>New England Journal of Medicine</i> , 2012, 367, 1297-1309.	27.0	765
3	Association Between Hospital Process Performance and Outcomes Among Patients With Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1912.	7.4	588
4	Excess Dosing of Antiplatelet and Antithrombin Agents in the Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 3108.	7.4	587
5	Utilization of Early Invasive Management Strategies for High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 2096.	7.4	525
6	Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1923-1932.	2.8	404
7	Treatments, Trends, and Outcomes of Acute Myocardial Infarction and Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2010, 56, 254-263.	2.8	382
8	Evolution in Cardiovascular Care for Elderly Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1479-1487.	2.8	297
9	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 133-144.	2.8	296
10	A Contemporary View of Diagnostic Cardiac Catheterization and Percutaneous Coronary Intervention in the United States. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2017-2031.	2.8	268
11	Pay for Performance, Quality of Care, and Outcomes in Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 2373.	7.4	254
12	Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. <i>Journal of the American College of Cardiology</i> , 2001, 37, 9-18.	2.8	235
13	Mortality of Myocardial Infarction by Sex, Age, and Obstructive Coronary Artery Disease Status in the ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get It Together). <i>Journal of the American College of Cardiology</i> , 2011, 58, 2642-2650.	2.8	210
14	Impact of Body Weight and Extreme Obesity on the Presentation, Treatment, and In-Hospital Outcomes of 50,149 Patients With ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2642-2650.	2.8	210
15	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 618-628.	11.4	207
16	In-Hospital Major Bleeding During ST-Elevation and Non-ST-Elevation Myocardial Infarction Care: Derivation and Validation of a Model from the ACTION Registry-GWTG. <i>American Journal of Cardiology</i> , 2011, 107, 1136-1143.	1.6	202
17	Intracoronary KAI-9803 as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction. <i>Circulation</i> , 2008, 117, 886-896.	1.6	200
18	Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1785.	7.4	200

#	ARTICLE	IF	CITATIONS
19	Using Digital Health Technology to Better Generate Evidence and Deliver Evidence-Based Care. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2680-2690.	2.8	192
20	Clinical and Therapeutic Profile of Patients Presenting With Acute Coronary Syndromes Who Do Not Have Significant Coronary Artery Disease. <i>Circulation</i> , 2000, 102, 1101-1106.	1.6	188
21	A Call to ACTION (Acute Coronary Treatment and Intervention Outcomes Network). <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 491-499.	2.2	187
22	Long-Term Mortality of Patients Undergoing Cardiac Catheterization for ST-Elevation and Non-ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2009, 119, 3110-3117.	1.6	184
23	Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. <i>Lancet</i> , 2017, 389, 1799-1808.	13.7	174
24	Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States. <i>Circulation: Cardiovascular Genetics</i> , 2016, 9, 240-249.	5.1	170
25	Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1167-1176.	2.8	154
26	Recent Trends in the Care of Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Archives of Internal Medicine</i> , 2006, 166, 2027.	3.8	153
27	Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: The Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry "Get With The Guidelines (GWTG)" acute myocardial infarction mortality model and risk score. <i>American Heart Journal</i> , 2011, 161, 113-122.e2.	2.7	149
28	Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2021, 384, 1981-1990.	27.0	145
29	Obesity and Age of First Non-ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2008, 52, 979-985.	2.8	140
30	Improving the Care of Patients with Non-ST-elevation Acute Coronary Syndromes in the Emergency Department: The CRUSADE Initiative. <i>Academic Emergency Medicine</i> , 2002, 9, 1146-1155.	1.8	137
31	Cardiovascular Care Facts. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1931-1947.	2.8	135
32	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 387-396.	2.8	131
33	Elderly Patients With Acute Coronary Syndromes Managed Without Revascularization. <i>Circulation</i> , 2013, 128, 823-833.	1.6	130
34	Gaps in Referral to Cardiac Rehabilitation of Patients Undergoing Percutaneous Coronary Intervention in the United States. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2079-2088.	2.8	130
35	Temporal Trends in and Factors Associated With Bleeding Complications Among Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1861-1869.	2.8	129
36	Quality of Care by Classification of Myocardial Infarction. <i>Archives of Internal Medicine</i> , 2005, 165, 1630.	3.8	128

#	ARTICLE	IF	CITATIONS
37	Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction. Journal of the American College of Cardiology, 2003, 42, 45-53.	2.8	126
38	The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes. American Heart Journal, 2006, 151, 1205-1213.	2.7	126
39	Improving the Care of Patients with Non-ST-elevation Acute Coronary Syndromes in the Emergency Department: The CRUSADE Initiative. Academic Emergency Medicine, 2002, 9, 1146-1155.	1.8	122
40	Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: The Targeted platelet Inhibition to Clarify the Optimal strategy to medically manage Acute Coronary Syndromes (TRILOGY) Trial. JAMA, 2009, 302, 1017-1025.	2.7	120
41	Culprit-only or multivessel revascularization in patients with acute coronary syndromes. American Heart Journal, 2008, 155, 140-146.	2.7	115
42	Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the Targeted platelet Inhibition to Clarify the Optimal strategy to medically manage Acute Coronary Syndromes (TRILOGY ACS) trial. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 231-242.	1.0	110
43	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation, 2019, 140, 103-112.	1.6	107
44	Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet, The, 2013, 382, 605-613.	13.7	105
45	Outcomes of PCI in Relation to Procedural Characteristics and Operator Volumes in the United States. Journal of the American College of Cardiology, 2017, 69, 2913-2924.	2.8	104
46	Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome. Circulation, 2020, 141, 1608-1617.	1.6	104
47	Emergency Department Bypass for ST-Segment Elevation Myocardial Infarction Patients Identified With a Prehospital Electrocardiogram. Circulation, 2013, 128, 352-359.	1.6	101
48	Prevalence and Outcomes of Same-Day Discharge After Elective Percutaneous Coronary Intervention Among Older Patients. JAMA - Journal of the American Medical Association, 2011, 306, 1461.	7.4	95
49	The China Acute Myocardial Infarction (CAMI) Registry: A national long-term registry-research-education integrated platform for exploring acute myocardial infarction in China. American Heart Journal, 2016, 175, 193-201.e3.	2.7	95
50	Targeting Vascular Calcification in Chronic Kidney Disease. JACC Basic To Translational Science, 2020, 5, 398-412.	4.1	95
51	Comparative Efficacy and Safety of Oral P2Y ₁₂ Inhibitors in Acute Coronary Syndrome. Circulation, 2020, 142, 150-160.	1.6	93
52	Implications and reasons for the lack of use of reperfusion therapy in patients with ST-segment elevation myocardial infarction: Findings from the CRUSADE initiative. American Heart Journal, 2010, 159, 757-763.	2.7	91
53	Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. New England Journal of Medicine, 2019, 381, 2479-2481.	27.0	91
54	Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. European Heart Journal, 2014, 35, 2516-2523.	2.2	83

#	ARTICLE	IF	CITATIONS
55	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. <i>Circulation</i> , 2019, 140, 2054-2062.	1.6	83
56	Early Clopidogrel Versus Prasugrel Use Among Contemporary STEMI and NSTEMI Patients in the US: Insights From the National Cardiovascular Data Registry. <i>Journal of the American Heart Association</i> , 2014, 3, e000849.	3.7	82
57	Predicting long-term mortality in older patients after non-ST-segment elevation myocardial infarction: The CRUSADE long-term mortality model and risk score. <i>American Heart Journal</i> , 2011, 162, 875-883.e1.	2.7	80
58	The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1898-1907.	2.8	75
59	Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. <i>Circulation</i> , 2021, 144, 1295-1307.	1.6	75
60	Fibrinolysis Use Among Patients Requiring Interhospital Transfer for ST-Segment Elevation Myocardial Infarction Care. <i>JAMA Internal Medicine</i> , 2015, 175, 207.	5.1	72
61	The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2012, 33, 2044-2053.	2.2	71
62	Polyvascular Disease and Long-Term Cardiovascular Outcomes in Older Patients With Non-ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 541-549.	2.2	65
63	Frequency, Predictors, and Outcomes of Drug-Eluting Stent Utilization in Patients With High-Risk Non-ST-Segment Elevation Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2005, 96, 750-755.	1.6	63
64	Relationship Between Cancer and Cardiovascular Outcomes Following Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	62
65	Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus. <i>Circulation</i> , 2020, 141, 843-862.	1.6	62
66	Longitudinal Risk of Adverse Events in Patients With Acute Kidney Injury After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	61
67	Data monitoring committees: Promoting best practices to address emerging challenges. <i>Clinical Trials</i> , 2017, 14, 115-123.	1.6	61
68	Changing the model of care for patients with acute coronary syndromes. <i>American Heart Journal</i> , 2003, 146, 605-612.	2.7	58
69	Documented traditional cardiovascular risk factors and mortality in non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2007, 153, 507-514.	2.7	58
70	Long-Term Mortality of Older Patients With Acute Myocardial Infarction Treated in US Clinical Practice. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	58
71	US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1223-1229.	1.5	57
72	Defining Heart Failure End Points in ST-Segment Elevation Myocardial Infarction Trials. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 594-600.	2.2	53

#	ARTICLE	IF	CITATIONS
73	Patterns of transfer for patients with non- ST -segment elevation acute coronary syndrome from community to tertiary care hospitals. <i>American Heart Journal</i> , 2008, 156, 185-192.	2.7	52
74	The paradoxical use of cardiac catheterization in patients with non- ST -elevation acute coronary syndromes: Lessons from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC /AHA Guidelines (CRUSADE) Quality Improvement Initiative. <i>American Heart Journal</i> , 2009, 158, 263-270.	2.7	52
75	Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Non- ST Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 197-205.	2.2	52
76	Development of Systems of Care for ST-Elevation Myocardial Infarction Patients. <i>Circulation</i> , 2007, 116, e68-72.	1.6	51
77	Comparison of the Prognostic Value of Peak Creatine Kinase- MB and Troponin Levels Among Patients With Acute Myocardial Infarction: A Report from the Acute Coronary Treatment and Intervention Outcomes Network Registry- $\text{Get With The Guidelines}$. <i>Clinical Cardiology</i> , 2012, 35, 424-429.	1.8	51
78	Potent P2Y ₁₂ Inhibitors in Men Versus Women. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1549-1559.	2.8	51
79	Days Alive and Out of Hospital: Exploring a Patient-Centered, Pragmatic Outcome in a Clinical Trial of Patients With Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004755.	2.2	51
80	Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. <i>European Heart Journal</i> , 2020, 41, 2248-2258.	2.2	51
81	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 162-171.	2.8	50
82	Comparative trends in guidelines adherence among patients with non- ST -segment elevation acute coronary syndromes treated with invasive versus conservative management strategies: Results from the CRUSADE quality improvement initiative. <i>American Heart Journal</i> , 2009, 158, 748-754.e1.	2.7	49
83	In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 585-593.	3.9	49
84	Nationwide Analysis of Patients With ST-Segment Elevation Myocardial Infarction Transferred for Primary Percutaneous Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	3.9	49
85	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1177-1186.	2.8	49
86	Prevalence, Predictors, and Impact of Conservative Medical Management for Patients With Non- ST -Segment Elevation Acute Coronary Syndromes Who Have Angiographically Documented Significant Coronary Disease. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 369-378.	2.9	48
87	Warfarin use among older atrial fibrillation patients with non- ST -segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy. <i>American Heart Journal</i> , 2013, 166, 864-870.	2.7	46
88	Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non- ST elevation myocardial infarction. <i>American Heart Journal</i> , 2012, 163, 720-728.	2.7	45
89	Relationship Between Risk Stratification by Cardiac Troponin Level and Adherence to Guidelines for Non- ST -Segment Elevation Acute Coronary Syndromes. <i>Archives of Internal Medicine</i> , 2005, 165, 1870.	3.8	44
90	Impact of Congestive Heart Failure in Patients With Non- ST -Segment Elevation Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2006, 97, 1707-1712.	1.6	44

#	ARTICLE	IF	CITATIONS
91	Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. <i>European Heart Journal</i> , 2015, 36, 385-392.	2.2	44
92	Temporal Trends in the Use of Early Cardiac Catheterization in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (Results from CRUSADE). <i>American Journal of Cardiology</i> , 2006, 98, 1172-1176.	1.6	43
93	Temporal Changes in the Use of Drug-Eluting Stents for Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention From 2006 to 2008. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 414-420.	2.2	43
94	Association of Early Physician Follow-Up and 30-Day Readmission After Non-ST-Segment Elevation Myocardial Infarction Among Older Patients. <i>Circulation</i> , 2013, 128, 1206-1213.	1.6	43
95	Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 443-454.	1.0	43
96	Relationship Between Operator Volume and Long-Term Outcomes After Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 139, 458-472.	1.6	43
97	Differences in Short- and Long-Term Outcomes Among Older Patients With ST-Elevation Versus Non-ST-Elevation Myocardial Infarction With Angiographically Proven Coronary Artery Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 513-522.	2.2	42
98	Challenges in Predicting the Need for Coronary Artery Bypass Grafting at Presentation in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2006, 98, 624-627.	1.6	41
99	Influence of Inpatient Service Specialty on Care Processes and Outcomes for Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2007, 116, 1153-1161.	1.6	41
100	Paradoxical use of invasive cardiac procedures for patients with non-ST segment elevation myocardial infarction: An international perspective from the CRUSADE Initiative and the Canadian ACS Registries I and II. <i>Canadian Journal of Cardiology</i> , 2007, 23, 1073-1079.	1.7	41
101	Temporal Trends in the Risk Profile of Patients Undergoing Outpatient Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e003070.	3.9	41
102	Association of Body Mass Index and Long-Term Outcomes in Older Patients With Non-ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 102-109.	2.2	40
103	Changes in Patterns of Coronary Revascularization Strategies for Patients With Acute Coronary Syndromes (from the CRUSADE Quality Improvement Initiative). <i>American Journal of Cardiology</i> , 2007, 99, 1222-1226.	1.6	39
104	Regional Patterns of Use of a Medical Management Strategy for Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 205-213.	2.2	39
105	Impact of Diabetes Mellitus on Clinical Characteristics, Management, and In-hospital Outcomes in Patients With Acute Myocardial Infarction (from the NCDR). <i>American Journal of Cardiology</i> , 2014, 114, 1136-1144.	1.6	39
106	Characteristics, Management, and Outcomes of Cocaine-Positive Patients With Acute Coronary Syndrome (from the National Cardiovascular Data Registry). <i>American Journal of Cardiology</i> , 2014, 113, 749-756.	1.6	38
107	A New Era in Secondary Prevention after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2012, 366, 85-87.	27.0	35
108	Cumulative Incidence of Death and Rehospitalization Among the Elderly in the First Year after NSTEMI. <i>American Journal of Medicine</i> , 2015, 128, 582-590.	1.5	35

#	ARTICLE	IF	CITATIONS
109	Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2016, 67, 936-947.	2.8	35
110	Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes. <i>Heart</i> , 2017, 103, 1168-1176.	2.9	34
111	Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2015, 169, 257-265.e1.	2.7	33
112	Cardiac arrest and clinical characteristics, treatments and outcomes among patients hospitalized with ST-elevation myocardial infarction in contemporary practice: A report from the National Cardiovascular Data Registry. <i>American Heart Journal</i> , 2015, 169, 515-522.e1.	2.7	33
113	Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 33-43.	1.8	33
114	Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes. <i>European Heart Journal</i> , 2008, 29, 2480-2488.	2.2	31
115	Characteristics and Outcomes in Patients Undergoing Percutaneous Coronary Intervention Following Cardiac Arrest (from the NCDR). <i>American Journal of Cardiology</i> , 2014, 113, 1087-1092.	1.6	31
116	Guideline Implementation Research: Exploring the Gap between Evidence and Practice in the CRUSADE Quality Improvement Initiative. <i>Academic Emergency Medicine</i> , 2007, 14, 949-954.	1.8	30
117	Use of and in-hospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: Results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE). <i>American Heart Journal</i> , 2008, 156, 606-612.	2.7	30
118	Differences in Short-Term Versus Long-Term Outcomes of Older Black Versus White Patients With Myocardial Infarction. <i>Circulation</i> , 2014, 130, 659-667.	1.6	30
119	Neighborhood Socioeconomic Disadvantage and Care After Myocardial Infarction in the National Cardiovascular Data Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004054.	2.2	30
120	Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer. <i>JACC: CardioOncology</i> , 2020, 2, 70-81.	4.0	30
121	A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. <i>American Heart Journal</i> , 2016, 174, 120-128.	2.7	29
122	Contemporary Patterns of Discharge Aspirin Dosing After Acute Myocardial Infarction in the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 701-707.	2.2	28
123	Effectiveness of Arterial Closure Devices for Preventing Complications With Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e003464.	3.9	28
124	Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. <i>American Heart Journal</i> , 2015, 170, 683-694.e3.	2.7	26
125	Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. <i>American Heart Journal</i> , 2017, 187, 194-203.	2.7	26
126	Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. <i>European Heart Journal</i> , 2016, 37, ehv611.	2.2	25

#	ARTICLE	IF	CITATIONS
127	Whole blood sequencing reveals circulating microRNA associations with high-risk traits in non-ST-segment elevation acute coronary syndrome. <i>Atherosclerosis</i> , 2017, 261, 19-25.	0.8	25
128	Prognostic implications of creatine kinase-MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. <i>American Heart Journal</i> , 2014, 168, 503-511.e2.	2.7	24
129	Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. <i>International Journal of Cardiology</i> , 2017, 241, 87-96.	1.7	24
130	Timing of Glycoprotein IIb/IIIa Inhibitor Use and Outcomes Among Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention (Results from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 61)	2.7	24
131	Association of chronic lung disease with treatments and outcomes patients with acute myocardial infarction. <i>American Heart Journal</i> , 2013, 165, 43-49.	2.7	23
132	Medication Discontinuation in the IMPROVE-IT Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005041.	2.2	23
133	Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial. <i>American Heart Journal</i> , 2014, 168, 76-87.e1.	2.7	22
134	The association of in-hospital guideline adherence and longitudinal postdischarge mortality in older patients with non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2015, 170, 273-280.e1.	2.7	22
135	Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2016, 1, 73.	6.1	22
136	Comparison of Delay Times from Symptom Onset to Medical Contact in Blacks Versus Whites With Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2017, 119, 1127-1134.	1.6	22
137	Relationship of the Distance Between Non-PCI Hospitals and Primary PCI Centers, Mode of Transport, and Reperfusion Time Among Ground and Air Interhospital Transfers Using NCDR's ACTION Registry-GWTG. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 797-805.	3.9	21
138	Noninvasive, medical management for non-ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , 2008, 155, 397-407.	2.7	20
139	The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarction. <i>American Heart Journal</i> , 2012, 163, 705-713.	2.7	20
140	The association between smoking and long-term outcomes after non-ST-segment elevation myocardial infarction in older patients. <i>American Heart Journal</i> , 2013, 166, 1056-1062.	2.7	20
141	A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. <i>American Heart Journal</i> , 2016, 181, 92-100.	2.7	20
142	Meta-Analysis of Intracranial Hemorrhage in Acute Coronary Syndromes: Incidence, Predictors, and Clinical Outcomes. <i>Journal of the American Heart Association</i> , 2015, 4, e001512.	3.7	19
143	Assessment of Operator Variability in Risk-Standardized Mortality Following Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 672-682.	2.9	19
144	Seasonal and circadian patterns of myocardial infarction by coronary artery disease status and sex in the ACTION Registry-GWTG. <i>International Journal of Cardiology</i> , 2019, 274, 16-20.	1.7	19

#	ARTICLE	IF	CITATIONS
145	Long-term outcomes among older patients with non-ST-segment elevation myocardial infarction complicated by cardiogenic shock. <i>American Heart Journal</i> , 2013, 166, 298-305.	2.7	18
146	Influence of Presenting Electrocardiographic Findings on the Treatment and Outcomes of Patients With Non-ST-Segment Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2014, 113, 256-261.	1.6	18
147	Direct Transfer From the Referring Hospitals to the Catheterization Laboratory to Minimize Reperfusion Delays for Primary Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002477.	3.9	18
148	Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: Insights from the Targeted platelet Inhibition to Clarify the Optimal strategy to medically manage Acute Coronary Syndromes trial. <i>American Heart Journal</i> , 2015, 170, 695-705.e5.	2.7	18
149	One and done: Reasons principal investigators conduct only one FDA-regulated drug trial. <i>Contemporary Clinical Trials Communications</i> , 2017, 6, 31-38.	1.1	18
150	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. <i>Circulation</i> , 2019, 139, 863-873.	1.6	18
151	Androgen deprivation therapy and cardiovascular disease. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 45-52.	1.6	18
152	Relation of Admission High-Density Lipoprotein Cholesterol Level and In-Hospital Mortality in Patients With Acute Non-ST Segment Elevation Myocardial Infarction (from the National Cardiovascular Data) <i>TJ ETQq0 0 0 rgt /Overlback 10 Tf</i>		
153	The Impact of Bleeding Avoidance Strategies on Hospital-Level Variation in Bleeding Rates Following Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 771-779.	2.9	17
154	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005858.	2.2	17
155	Independent data monitoring committees: Preparing a path for the future. <i>American Heart Journal</i> , 2014, 168, 135-141.e1.	2.7	16
156	Do patients treated at academic hospitals have better longitudinal outcomes after admission for non-ST-elevation myocardial infarction?. <i>American Heart Journal</i> , 2014, 167, 762-769.	2.7	16
157	Implications of prior myocardial infarction for patients presenting with an acute myocardial infarction. <i>American Heart Journal</i> , 2014, 167, 840-845.	2.7	16
158	Association of acute myocardial infarction cardiac arrest patient volume and in-hospital mortality in the United States: Insights from the National Cardiovascular Data Registry Acute Coronary Treatment And Intervention Outcomes Network Registry. <i>Clinical Cardiology</i> , 2019, 42, 352-357.	1.8	16
159	Factors Associated With Off-Label Use of Drug-Eluting Stents in Patients With ST-Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2008, 101, 286-292.	1.6	15
160	Long-Term Outcomes After Invasive Management for Older Patients With Non-ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 323-332.	2.2	15
161	Predictors of Reperfusion Delay in Patients With ST Elevation Myocardial Infarction Self-Transported to the Hospital (from the American Heart Association's Mission: Lifeline Program). <i>American Journal of Cardiology</i> , 2014, 113, 798-802.	1.6	15
162	The future of cardiovascular clinical research in North America and beyond—addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. <i>American Heart Journal</i> , 2015, 169, 743-750.	2.7	15

#	ARTICLE	IF	CITATIONS
163	Spontaneous MI After Non-“ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1289-1297.	2.8	15
164	Percutaneous coronary intervention for older adults who present with syncope and coronary artery disease? Insights from the National Cardiovascular Data Registry. <i>American Heart Journal</i> , 2016, 176, 1-9.	2.7	15
165	The National Cardiovascular Data Registry Data Quality Program 2020. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1704-1712.	2.8	15
166	Impact of Human Development Index on the profile and outcomes of patients with acute coronary syndrome. <i>Heart</i> , 2015, 101, 279-286.	2.9	14
167	Administrative claims data to support pragmatic clinical trial outcome ascertainment on cardiovascular health. <i>Clinical Trials</i> , 2019, 16, 419-430.	1.6	14
168	Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements. <i>Scientific Reports</i> , 2020, 10, 6169.	3.3	14
169	Influence of heart failure symptoms and ejection fraction on short- and long-term outcomes for older patients with non-“ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2014, 167, 267-273.e1.	2.7	13
170	Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease. <i>Drug Safety</i> , 2016, 39, 715-727.	3.2	12
171	Utilization, Characteristics, and In-Hospital Outcomes of Coronary Artery Bypass Grafting in Patients With ST-Segment-“Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	12
172	Elevated Uric Acid Prevalence and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from RELAX. <i>American Journal of Medicine</i> , 2020, 133, e716-e721.	1.5	12
173	Careers for Clinician Investigators. <i>Circulation</i> , 2009, 119, 2945-2950.	1.6	11
174	Hospital patterns of medical management strategy use for patients with non-“ST-elevation myocardial infarction and 3-vessel or left main coronary artery disease. <i>American Heart Journal</i> , 2014, 167, 355-362.e3.	2.7	11
175	Time to treatment as a quality metric for acute STEMI care. <i>Lancet, The</i> , 2015, 385, 1056-1057.	13.7	10
176	Indications, algorithms, and outcomes for coronary artery bypass surgery in patients with acute coronary syndromes. <i>Coronary Artery Disease</i> , 2016, 27, 319-326.	0.7	10
177	Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes. <i>Stroke</i> , 2016, 47, 1135-1139.	2.0	10
178	Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization. <i>American Heart Journal</i> , 2017, 188, 156-166.	2.7	10
179	Blood pressure paradox in patients with non-“ST-segment elevation acute coronary syndromes. <i>American Heart Journal</i> , 2009, 157, 525-531.	2.7	9
180	Translational platelet research in patients with coronary artery disease: What are the major knowledge gaps?. <i>Thrombosis and Haemostasis</i> , 2012, 108, 12-20.	3.4	9

#	ARTICLE	IF	CITATIONS
181	Trends in outcomes among older patients with non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2014, 167, 36-42.e1.	2.7	9
182	Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2017, 63, 1214-1226.	3.2	9
183	Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. <i>American Heart Journal</i> , 2018, 201, 25-32.	2.7	9
184	P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2019, 4, 680.	6.1	9
185	Enabling patient-reported outcome measures in clinical trials, exemplified by cardiovascular trials. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 164.	2.4	9
186	Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: Validity, pitfalls, and future approaches. <i>American Heart Journal</i> , 2013, 165, 644-654.e1.	2.7	8
187	The Contemporary Use of Angiography and Revascularization Among Patients With Non-ST-Segment Elevation Myocardial Infarction in the United States Compared With South Korea. <i>Clinical Cardiology</i> , 2015, 38, 708-714.	1.8	8
188	Relationship Between Peak Troponin Values and Long-Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	8
189	Navigating the Future of Cardiovascular Drug Development—Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 445-458.	2.6	8
190	Association of acute kidney injury and chronic kidney disease with processes of care and long-term outcomes in patients with acute myocardial infarction. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2018, 4, 43-50.	4.0	8
191	Hospital participation in clinical trials for patients with acute myocardial infarction: Results from the National Cardiovascular Data Registry. <i>American Heart Journal</i> , 2019, 214, 184-193.	2.7	8
192	Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout. <i>American Journal of Cardiology</i> , 2020, 127, 64-72.	1.6	8
193	Relation of Patient Age and Mortality to Reported Contraindications to Early Beta-Blocker Use for Non-ST-Elevation Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2009, 104, 1324-1329.	1.6	7
194	Public Sensationalism and Clinical Trials: How to Address the Challenges of Science?. <i>American Journal of Medicine</i> , 2010, 123, 481-483.	1.5	7
195	Statin Treatment by Low-Density Lipoprotein Cholesterol Levels in Patients With Non-ST-Segment Elevation Myocardial Infarction/Unstable Angina Pectoris (from the CRUSADE Registry). <i>American Journal of Cardiology</i> , 2015, 115, 1655-1660.	1.6	7
196	Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-Term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial. <i>Clinical Cardiology</i> , 2016, 39, 329-337.	1.8	7
197	Treatment of coronary artery disease in cancer survivors. <i>Coronary Artery Disease</i> , 2017, 28, 1-2.	0.7	7
198	Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. <i>American Heart Journal</i> , 2019, 218, 110-122.	2.7	7

#	ARTICLE	IF	CITATIONS
199	Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT). <i>American Journal of Cardiology</i> , 2019, 123, 1193-1201.	1.6	7
200	Sex And Prognostic Significance of Self-Reported Frailty in Nonâ€“ST-Segment Elevation Acute Coronary Syndromes: Insights From the TRILOGY ACS Trial. <i>Canadian Journal of Cardiology</i> , 2019, 35, 430-437.	1.7	7
201	Comparison of long-term outcomes between older Asian and white patients with nonâ€“ST-segment elevation myocardial infarction: Findings from CRUSADE-CMS database. <i>American Heart Journal</i> , 2013, 166, 1050-1055.	2.7	6
202	What is the best ST-segment recovery parameter to predict clinical outcome and myocardial infarct size? Amplitude, speed, and completeness of ST-segment recovery after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. <i>Journal of Electrocardiology</i> , 2017, 50, 952-959.	0.9	6
203	Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy. <i>European Heart Journal</i> , 2018, 39, 193-200.	2.2	6
204	Limitations of using cardiac catheterization rates to assess the quality of care for patients with nonâ€“ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2012, 164, 502-508.	2.7	5
205	Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the <scp>TRILOGY ACS</scp> Trial. <i>Clinical Cardiology</i> , 2016, 39, 497-506.	1.8	5
206	Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006582.	2.2	5
207	Early Treatment for Nonâ€“STâ€“Segment Elevation Acute Coronary Syndrome Is Associated with Appropriate Discharge Care. <i>Clinical Cardiology</i> , 2009, 32, 519-525.	1.8	4
208	Excess of Solid Cancers After Prasugrel. <i>American Journal of Therapeutics</i> , 2016, 23, e243-e244.	0.9	4
209	Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Nonâ€“STâ€“Segment Elevation Myocardial Infarction Discharged Without Inâ€“hospital Revascularization. <i>Journal of the American Heart Association</i> , 2016, 5, e002784.	3.7	4
210	Relationship of Platelet Reactivity With Bleeding Outcomes During Longâ€“Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Nonâ€“STâ€“Segment Elevation Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	4
211	Pooled analysis of adverse event collection from 4 acute coronary syndrome trials. <i>American Heart Journal</i> , 2016, 174, 60-67.	2.7	4
212	Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes. <i>Coronary Artery Disease</i> , 2018, 29, 469-476.	0.7	4
213	Associations of osteopontin and NT-proBNP with circulating miRNA levels in acute coronary syndrome. <i>Physiological Genomics</i> , 2019, 51, 506-515.	2.3	4
214	Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference. <i>American Journal of Kidney Diseases</i> , 2020, 76, 842-850.	1.9	4
215	Preexisting frailty and outcomes in older patients with acute myocardial infarction. <i>American Heart Journal</i> , 2022, 249, 34-44.	2.7	4
216	The Association of Transfer Rate From Hospitals Without Revascularization Capabilities and Mortality Risk for Older Nonâ€“<scp>ST</scp>â€“Segment Elevation Myocardial Infarction Patients. <i>Clinical Cardiology</i> , 2015, 38, 733-739.	1.8	3

#	ARTICLE	IF	CITATIONS
217	Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. <i>Heart</i> , 2016, 102, 1221-1229.	2.9	3
218	Health-related quality of life outcomes with prasugrel among medically managed non-“ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial. <i>American Heart Journal</i> , 2016, 178, 55-64.	2.7	3
219	Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort. <i>Clinical Cardiology</i> , 2017, 40, 899-906.	1.8	3
220	The impact of clinical vs administrative claims coding on hospital risk-adjusted outcomes. <i>Clinical Cardiology</i> , 2018, 41, 1225-1231.	1.8	3
221	Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials). <i>American Journal of Cardiology</i> , 2022, 178, 11-17.	1.6	3
222	Comprehensive electrocardiogram-to-device time for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: A report from the American Heart Association mission: Lifeline program. <i>American Heart Journal</i> , 2018, 197, 9-17.	2.7	2
223	Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non-“ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial). <i>American Journal of Cardiology</i> , 2018, 122, 1322-1329.	1.6	2
224	Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status. <i>American Journal of Cardiology</i> , 2018, 122, 1451-1458.	1.6	2
225	Addressing the Conundrum of Bleeding and Cancer Detection With Antithrombotic Therapies for Chronic Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2019, 140, 1460-1462.	1.6	2
226	Continuum of Care in the Treatment of ST-Segment Elevation Myocardial Infarction (STEMI): Importance of Platelet and Coagulation Inhibition. <i>Postgraduate Medicine</i> , 2008, 120, 67-78.	2.0	1
227	Overcoming the Risk-Treatment Paradox for Non-“ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1462-1464.	2.8	1
228	Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor. <i>American Journal of Cardiology</i> , 2020, 125, 1280-1283.	1.6	1
229	Abstract 13975: Association of In-Hospital Acute Kidney Injury With Long-term Outcomes in Survivors of Acute Myocardial Infarction: Insight From the NCDR. <i>Circulation</i> , 2015, 132, .	1.6	1
230	Insurance Coverage and Care of Patients with Non-“ST-Segment Elevation Acute Coronary Syndromes. <i>Annals of Internal Medicine</i> , 2007, 147, 212.	3.9	0
231	Lessons Learned from Negative Clinical Trials Evaluating Antithrombotic Therapy for Ischemic Heart Disease. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 112-125.	2.4	0
232	Uncovering the Shroud on Antiplatelet Therapy for Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 613-614.	2.9	0
233	Treatment for low-risk patients with STEMI—challenges remain. <i>Nature Reviews Cardiology</i> , 2014, 11, 440-442.	13.7	0
234	Rejoinder. <i>Clinical Trials</i> , 2017, 14, 126-127.	1.6	0

#	ARTICLE	IF	CITATIONS
235	Leveraging electronic health record data for pragmatic randomized trials. <i>Clinical Trials</i> , 2020, 17, 368-369.	1.6	0
236	Post-COVID-19 Syndrome: Leveraging the Patient Perspective and Technological Innovations to Enable the Delineation of Effective Treatments. <i>Drugs</i> , 2021, 81, 1235-1237.	10.9	0
237	Abstract 13846: The Relationship of Platelet Function Measurements with Bleeding Outcomes During Long-term Treatment with Dual Antiplatelet Therapy in Medically Managed NSTEMI-ACS Patients. <i>Circulation</i> , 2014, 130, .	1.6	0